MDxHealth S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MDXH research report →
Companymdxhealth.com
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
- CEO
- Michael K. McGarrity
- IPO
- 2021
- Employees
- 312
- HQ
- Herstal, BE
Price Chart
Valuation
- Market Cap
- $45.20M
- P/E
- -1.68
- P/S
- 0.56
- P/B
- -3.64
- EV/EBITDA
- -18.17
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 57.68%
- Op Margin
- -16.59%
- Net Margin
- -32.17%
- ROE
- 402.97%
- ROIC
- -12.74%
Growth & Income
- Revenue
- $107.88M · 19.80%
- Net Income
- $-33,519,000 · 11.95%
- EPS
- $-0.67 · 14.10%
- Op Income
- $-15,401,000
- FCF YoY
- 44.06%
Performance & Tape
- 52W High
- $5.33
- 52W Low
- $0.68
- 50D MA
- $2.29
- 200D MA
- $3.35
- Beta
- 0.38
- Avg Volume
- 459.16K
Get TickerSpark's AI analysis on MDXH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Bednarski Eric | other | 0 |
| Mar 18, 26 | Bellano John | other | 20,000 |
| Mar 18, 26 | Bellano John | other | 65,000 |
| Mar 18, 26 | Bellano John | other | 200,000 |
| Mar 18, 26 | McGarrity Michael | other | 0 |
| Mar 18, 26 | McGarrity Michael | other | 50,000 |
| Mar 18, 26 | McGarrity Michael | other | 186,875 |
| Mar 18, 26 | McGarrity Michael | other | 500,000 |
| Mar 18, 26 | Sollee Joseph | other | 20,000 |
| Mar 18, 26 | Sollee Joseph | other | 65,000 |
Our MDXH Coverage
We haven't published any research on MDXH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MDXH Report →